VivoSeq
Metabolic & Endocrine

Vitamin D Deficiency

17

Pipeline Programs

4

Active Trials

13

Companies Involved

Vitamin D Deficiency is an emerging landscape with 17 programs across 13 companies. The most active players are Eli Lilly, Novartis, AbbVie. 3 therapies are approved with 4 more in late-stage development.

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

0/100

Mech. Concentration

29/100

Completion Rate

81/100

Attrition Rate

14/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

42

clinical trials

Completed26 · 62%
Unknown status6 · 14%
Terminated5 · 12%
Recruiting2 · 5%
Withdrawn1 · 2%
Not yet recruiting1 · 2%
Other1 · 2%

Trial Activity

42 trials

Rapid Normalization of Vitamin D Deficiency in PICU
Completed··Phase 3·NCT03742505·424 enrolled
VITdAL@ICU - Correction of Vitamin D Deficiency in Critically Ill Patients
Completed··Phase 3·NCT01130181·480 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)